Objective: Diabetic nephropathy (DN), a critical complication of diabetes, is characterized by progressive renal function impairment and fibrosis development. F-box and WD repeat domain-containing 7 (FBXW7), an E3 ubiquitin ligase, is recognized for its role in metabolic disorders; however, its specific functions and mechanisms in DN remain incompletely understood. This study aimed to clarify the role of FBXW7 in the pathogenesis of DN. Methods: Mouse tubular epithelial cells (mTECs) cultured under hyperglycemic conditions were used. FBXW7 overexpression was induced in the kidneys of db/db mice and in mTECs to evaluate its effects on renal fibrosis and related molecular pathways. The interaction between FBXW7 and metadherin (Mtdh) was examined by using co-immunoprecipitation and Western blotting techniques. Results: FBXW7 expression was found to be significant reduced in the kidneys of DN patients and db/db mice. Overexpression of FBXW7 markedly improved albuminuria, blood urea nitrogen, uric acid levels, and renal fibrosis in db/db mice. Additionally, FBXW7 was shown to inhibit high glucose-induced fibrosis in mTECs through a mechanism involving the ubiquitin-mediated degradation of Mtdh, a protein known to promote fibrosis. Suppression of Mtdh via FBXW7 overexpression was also linked to inactivation of TGF-β/Smad3 signaling in DN. Conclusion: These findings highlight the protective role of FBXW7 in DN by downregulating Mtdh and indicate that FBXW7 represents a promising therapeutic target for DN.
Rationale: Systemic lupus erythematosus (SLE) is a complex autoimmune disease that affects various organs. Disease activity in SLE may diminish following the initiation of dialysis in patients with end-stage renal disease. Patient concern: We report the case of a 69-year-old female patient with a prior diagnosis of IgA nephropathy who developed SLE characterized by severe thrombocytopenia after hemodialysis. Diagnoses: The patient presented with fever, rash, polyarthralgia, thrombocytopenia, hemolytic anemia, positive antinuclear antibodies, anti-nucleosome antibodies, anticardiolipin antibodies, anti-β2-glycoprotein I antibodies, and decreased complement C3 and C4 levels. She was diagnosed with SLE complicated by hematological damage and immune thrombocytopenia. Interventions: The treatment included an intravenous infusion of 5% human immunoglobulin at 20 g/day for 5 days combined with an intravenous infusion of methylprednisolone at 500 mg/day for 3 days. Plasma exchange therapy was conducted a total of 3 times. Outcomes: The patient was discharged with methylprednisolone and hydroxychloroquine treatment. The platelet count was stable, antinuclear antibody, anti-nucleosome antibody, antiphospholipid antibody, Coombs test, and complement C3 and C4 levels were normal after discharge. Lessons: In patients with unexplained thrombocytopenia, the possibility of SLE should be considered even after hemodialysis initiation.